8 meta-analysis results to guide diabetes drug choice

Study clarifies the effects of SGLT2 inhibitors and GLP1 agonists on cardiovascular and renal outcomes

A meta-analysis has compared SGLT2 inhibitors and GLP1 receptor agonists for their effects on cardiovascular and renal outcomes in people with type 2 diabetes.